https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-02-01 / J Med Virol 2023 Feb;95(2):e28554
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-02-01 / J Med Virol 2023 Feb;95(2):e285542023-02-01 00:00:002025-09-06 13:30:27Tumor cell vaccine combined with Newcastle disease virus promote immunotherapy of lung cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2022-01-01 / Integr Cancer Ther 2022;21:15347354221083968
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2022-01-01 / Integr Cancer Ther 2022;21:153473542210839682022-01-01 00:00:002023-03-22 14:40:49A Single-Arm Phase II Study to Evaluate Efficacy and Safety of First-Line Treatment With DCVAC/LuCa, Standard of Care Chemotherapy and Shenqi Fuzheng Injection in Advanced (Stage IIIB/IV) Non-Small Cell Lung Cancer Patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-12-24 / ESMO Open 2022 Feb;7(1):100334
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-12-24 / ESMO Open 2022 Feb;7(1):1003342021-12-24 00:00:002023-03-22 14:40:50Safety and efficacy of dendritic cell-based immunotherapy (DCVAC/LuCa) combined with carboplatin/pemetrexed for patients with advanced non-squamous non-small-cell lung cancer without oncogenic drivers
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-11-24 / World J Clin Oncol 2021 Nov;12(11):966-982
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-11-24 / World J Clin Oncol 2021 Nov;12(11):966-9822021-11-24 00:00:002023-03-22 14:41:40Modulation of the immune response by heterogeneous monocytes and dendritic cells in lung cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-11-02 / Cancers (Basel) 2021 Nov;13(21)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-11-02 / Cancers (Basel) 2021 Nov;13(21)2021-11-02 00:00:002023-03-22 14:41:41Neoantigen Dendritic Cell Vaccination Combined with Anti-CD38 and CpG Elicits Anti-Tumor Immunity against the Immune Checkpoint Therapy-Resistant Murine Lung Cancer Cell Line LLC1
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-08-23 / Toxicol Appl Pharmacol 2021 Oct;429:115699
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-08-23 / Toxicol Appl Pharmacol 2021 Oct;429:1156992021-08-23 00:00:002021-08-23 00:00:00Targeting CD166 lung cancer stem cells: Molecular study using murine dendritic cell vaccine
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-04-21 / Oncol Lett 2021 Jun;21(6):482
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-04-21 / Oncol Lett 2021 Jun;21(6):4822021-04-21 00:00:002023-01-31 13:10:15MicroRNA-204 plays a role as a tumor suppressor in Newcastle disease virus-induced oncolysis in lung cancer A549 cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-03-17 / J Adv Res 2020 Jul;24:175-182
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-03-17 / J Adv Res 2020 Jul;24:175-1822020-03-17 00:00:002025-09-06 13:40:42A randomized phase II trial of best supportive care with or without hyperthermia and vitamin C for heavily pretreated, advanced, refractory non-small-cell lung cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-06-21 / J. Cell. Physiol. 2020 Jan;235(1):74-86
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-06-21 / J. Cell. Physiol. 2020 Jan;235(1):74-862019-06-21 00:00:002020-05-06 13:50:39Dendritic cell/cytokine-induced killer cell-based immunotherapy in lung cancer: What we know and future landscape
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-06-02 / J Clin Oncol 37, 2019 (suppl; abstr 9039)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-06-02 / J Clin Oncol 37, 2019 (suppl; abstr 9039)2019-06-02 00:00:002020-05-06 15:07:38Dendritic-cell vaccine (DCVAC) with first-line chemotherapy in patients with stage IV NSCLC: Final analysis of phase II, open label, randomized, multicenter trial.
